Apellis stock plunged Tuesday after third-quarter sales of the company's eye drug, Syfovre, widely missed Wall Street's expectations.
Apellis Pharmaceuticals (APLS) stock falls as company's Q3 2024 financials disappoint with lower-than-expected U.S. sales ...
Meibomian gland dysfunction assessments in children a highlight at the Tear Film & Ocular Surface Society's 2024 meeting.
LumiThera, Inc. today announced the U.S. FDA has authorized marketing of Valeda® Light Delivery System for patients with dry AMD.
PYC Therapeutics Limited (AU:PYC) has released an update. PYC Therapeutics has dosed its first patient in a clinical trial for its innovative ...
Science Corporation, a biotech startup launched by a Neuralink cofounder who left the company, claims that's achieved a ...
S cience Corporation, a rival to Elon Musk’s Neuralink in the development of brain-computer interface (BCI) technology, has just unveiled promising early clinical trial results for an eye implant that ...
It is caused by abnormal blood vessel growth (a condition referred to as 'wet' macular degeneration) or atrophy and accumulation of debris ('dry' macular degeneration), both of which damage the ...
The annual meeting of the American Academy of Ophthalmology was held from Oct. 18 to 21 in Chicago and attracted participants ...
Four months after Europe's Committee for Medicinal Products for Human Use (CHMP) rejected Apellis’ GA application for Syfovre for a second time, Astellas has withdrawn its application for the approval ...
Science Corporation's retinal implant allowed some people who lost their central vision to read, play cards, and recognize ...
One eye's AMD severity may affect AMD progression from the non neovascular to exudative form in the fellow eye.